vs
Side-by-side financial comparison of Royal Caribbean Group (RCL) and Viatris (VTRS). Click either name above to swap in a different company.
Royal Caribbean Group is the larger business by last-quarter revenue ($4.3B vs $3.7B, roughly 1.2× Viatris). On growth, Royal Caribbean Group posted the faster year-over-year revenue change (13.3% vs 5.0%). Viatris produced more free cash flow last quarter ($619.3M vs $116.0M). Over the past eight quarters, Royal Caribbean Group's revenue compounded faster (6.9% CAGR vs 0.5%).
Royal Caribbean Group, formerly known as Royal Caribbean Cruises Ltd., is a cruise holding company headquartered in Miami, Florida, United States and incorporated in Liberia. It is the world's second-largest cruise line operator, after Carnival Corporation & plc. As of September 2025, Royal Caribbean Group fully owns three cruise lines: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. It also holds a 50% stake in TUI Cruises, which operates Mein Schiff and Hapag-Lloyd ...
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
RCL vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.3B | $3.7B |
| Net Profit | $753.0M | — |
| Gross Margin | 47.4% | 31.1% |
| Operating Margin | 21.9% | -5.2% |
| Net Margin | 17.7% | — |
| Revenue YoY | 13.3% | 5.0% |
| Net Profit YoY | 36.4% | — |
| EPS (diluted) | $2.76 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.3B | $3.7B | ||
| Q3 25 | $5.1B | $3.7B | ||
| Q2 25 | $4.5B | $3.6B | ||
| Q1 25 | $4.0B | $3.2B | ||
| Q4 24 | $3.8B | $3.5B | ||
| Q3 24 | $4.9B | $3.7B | ||
| Q2 24 | $4.1B | $3.8B | ||
| Q1 24 | $3.7B | $3.7B |
| Q4 25 | $753.0M | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $730.0M | — | ||
| Q4 24 | $552.0M | — | ||
| Q3 24 | $1.1B | — | ||
| Q2 24 | $854.0M | — | ||
| Q1 24 | $360.0M | — |
| Q4 25 | 47.4% | 31.1% | ||
| Q3 25 | 51.8% | 36.6% | ||
| Q2 25 | 49.7% | 37.3% | ||
| Q1 25 | 48.0% | 35.8% | ||
| Q4 24 | 45.4% | 34.6% | ||
| Q3 24 | 51.1% | 39.0% | ||
| Q2 24 | 47.6% | 38.2% | ||
| Q1 24 | 44.8% | 41.2% |
| Q4 25 | 21.9% | -5.2% | ||
| Q3 25 | 33.1% | 4.8% | ||
| Q2 25 | 29.3% | 6.5% | ||
| Q1 25 | 23.6% | -88.9% | ||
| Q4 24 | 16.6% | -5.1% | ||
| Q3 24 | 33.4% | 6.0% | ||
| Q2 24 | 26.7% | -6.3% | ||
| Q1 24 | 20.1% | 5.6% |
| Q4 25 | 17.7% | — | ||
| Q3 25 | 30.6% | — | ||
| Q2 25 | 26.7% | — | ||
| Q1 25 | 18.3% | — | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 22.7% | — | ||
| Q2 24 | 20.8% | — | ||
| Q1 24 | 9.7% | — |
| Q4 25 | $2.76 | $-0.34 | ||
| Q3 25 | $5.74 | $-0.11 | ||
| Q2 25 | $4.41 | $0.00 | ||
| Q1 25 | $2.70 | $-2.55 | ||
| Q4 24 | $2.27 | $-0.43 | ||
| Q3 24 | $4.21 | $0.08 | ||
| Q2 24 | $3.11 | $-0.27 | ||
| Q1 24 | $1.35 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $825.0M | $1.3B |
| Total DebtLower is stronger | $18.2B | — |
| Stockholders' EquityBook value | $10.0B | $14.7B |
| Total Assets | $41.6B | $37.2B |
| Debt / EquityLower = less leverage | 1.81× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $825.0M | $1.3B | ||
| Q3 25 | $432.0M | $975.3M | ||
| Q2 25 | $735.0M | $566.4M | ||
| Q1 25 | $386.0M | $755.0M | ||
| Q4 24 | $388.0M | $734.8M | ||
| Q3 24 | $418.0M | $1.9B | ||
| Q2 24 | $391.0M | $917.2M | ||
| Q1 24 | $437.0M | $1.0B |
| Q4 25 | $18.2B | — | ||
| Q3 25 | $17.2B | — | ||
| Q2 25 | $17.6B | — | ||
| Q1 25 | $18.0B | — | ||
| Q4 24 | $18.5B | — | ||
| Q3 24 | $19.0B | — | ||
| Q2 24 | $19.8B | — | ||
| Q1 24 | $18.9B | — |
| Q4 25 | $10.0B | $14.7B | ||
| Q3 25 | $10.1B | $15.2B | ||
| Q2 25 | $9.2B | $15.6B | ||
| Q1 25 | $8.0B | $15.7B | ||
| Q4 24 | $7.6B | $18.6B | ||
| Q3 24 | $7.0B | $19.8B | ||
| Q2 24 | $6.0B | $19.5B | ||
| Q1 24 | $5.2B | $20.0B |
| Q4 25 | $41.6B | $37.2B | ||
| Q3 25 | $40.1B | $37.9B | ||
| Q2 25 | $38.5B | $38.4B | ||
| Q1 25 | $37.5B | $38.5B | ||
| Q4 24 | $37.1B | $41.5B | ||
| Q3 24 | $37.1B | $44.8B | ||
| Q2 24 | $37.0B | $45.3B | ||
| Q1 24 | $35.2B | $47.3B |
| Q4 25 | 1.81× | — | ||
| Q3 25 | 1.70× | — | ||
| Q2 25 | 1.92× | — | ||
| Q1 25 | 2.26× | — | ||
| Q4 24 | 2.44× | — | ||
| Q3 24 | 2.69× | — | ||
| Q2 24 | 3.29× | — | ||
| Q1 24 | 3.66× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.6B | $815.8M |
| Free Cash FlowOCF − Capex | $116.0M | $619.3M |
| FCF MarginFCF / Revenue | 2.7% | 16.8% |
| Capex IntensityCapex / Revenue | 35.4% | 5.3% |
| Cash ConversionOCF / Net Profit | 2.16× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.2B | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.6B | $815.8M | ||
| Q3 25 | $1.5B | $744.9M | ||
| Q2 25 | $1.7B | $219.7M | ||
| Q1 25 | $1.6B | $535.5M | ||
| Q4 24 | $1.5B | $482.7M | ||
| Q3 24 | $897.0M | $826.5M | ||
| Q2 24 | $1.6B | $379.1M | ||
| Q1 24 | $1.3B | $614.6M |
| Q4 25 | $116.0M | $619.3M | ||
| Q3 25 | $-989.0M | $658.1M | ||
| Q2 25 | $910.0M | $166.8M | ||
| Q1 25 | $1.2B | $492.9M | ||
| Q4 24 | $915.0M | $342.3M | ||
| Q3 24 | $563.0M | $749.5M | ||
| Q2 24 | $-567.0M | $320.3M | ||
| Q1 24 | $1.1B | $564.8M |
| Q4 25 | 2.7% | 16.8% | ||
| Q3 25 | -19.2% | 17.6% | ||
| Q2 25 | 20.1% | 4.7% | ||
| Q1 25 | 30.0% | 15.2% | ||
| Q4 24 | 24.3% | 9.7% | ||
| Q3 24 | 11.5% | 20.1% | ||
| Q2 24 | -13.8% | 8.5% | ||
| Q1 24 | 29.1% | 15.5% |
| Q4 25 | 35.4% | 5.3% | ||
| Q3 25 | 47.8% | 2.3% | ||
| Q2 25 | 18.4% | 1.5% | ||
| Q1 25 | 10.7% | 1.3% | ||
| Q4 24 | 14.7% | 4.0% | ||
| Q3 24 | 6.8% | 2.1% | ||
| Q2 24 | 52.1% | 1.6% | ||
| Q1 24 | 6.5% | 1.4% |
| Q4 25 | 2.16× | — | ||
| Q3 25 | 0.93× | — | ||
| Q2 25 | 1.44× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | 2.66× | — | ||
| Q3 24 | 0.81× | — | ||
| Q2 24 | 1.84× | — | ||
| Q1 24 | 3.69× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RCL
| Passenger | $2.9B | 69% |
| Other | $1.3B | 31% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
